,paragraph,value,label,name,type,company,sent,entity,entity_type_ext,sentence,phrases,qa_temp,key,score,question,answer,GPT3 Responses
0,"The aggregate market value of the voting stock held by non affiliates of the registrant as of June 30, 2021 was approximately $80.8 billion.",80.8,['Entity Public Float'],dei_EntityPublicFloat,monetaryItemType,ci,"The aggregate market value of the voting stock held by non affiliates of the registrant as of June 30, 2021 was approximately $80.8 billion.",approximately $80.8 billion,MONEY,"The aggregate market value of the voting stock held by non affiliates of the registrant as of June 30, 2021 was approximately $80.8 billion.","['aggregate market value of voting stock', 'non affiliates of registrant', 'aggregate market value', 'voting stock', 'non affiliates']","['aggregate market value of the voting stock', 0.27123400568962097, 'What is approximately $80.8 billion ?', 'aggregate market value of the voting stock']",aggregate market value of the voting stock,0.2712340056896209,What is approximately $80.8 billion ?,aggregate market value of the voting stock,the aggregate market value of the voting stock held by non affiliates of the registrant
1,"As of January 31, 2022, 320,953,245 shares of the registrant's Common Stock were outstanding.","320,953,245","['Entity Common Stock, Shares Outstanding']",dei_EntityCommonStockSharesOutstanding,sharesItemType,ci,"As of January 31, 2022, 320,953,245 shares of the registrant's Common Stock were outstanding.","320,953,245",CARDINAL,"As of January 31, 2022, 320,953,245 shares of the registrant's Common Stock were outstanding.","['shares of Common Stock', 'Common Stock']","['Common Stock', 0.8837555646896362, 'how many Common Stock ?', '320,953,245']",Common Stock,0.8837555646896362,how many Common Stock ?,"320,953,245",shares of the registrant's Common Stock
2,"(1) Par value per share, $0.01; shares issued, 394 million as of December 31, 2021 and 390 million as of December 31, 2020; authorized shares, 600 million.",394,"['Common stock, shares issued', 'Issued']",us-gaap_CommonStockSharesIssued,sharesItemType,ci,"(1) Par value per share, $0.01; shares issued, 394 million as of December 31, 2021 and 390 million as of December 31, 2020; authorized shares, 600 million.",394 million,CARDINAL,"1 Par value per share, $0.01; shares issued, 394 million as of December 31, 2021 and 390 million as of December 31, 2020; authorized shares, 600 million.","['Par value per share', 'shares']","['shares issued', 0.6108250021934509, 'What is 394 million ?', 'shares issued']",shares issued,0.6108250021934509,What is 394 million ?,shares issued,"shares issued as of December 31, 2021"
3,"(1) Par value per share, $0.01; shares issued, 394 million as of December 31, 2021 and 390 million as of December 31, 2020; authorized shares, 600 million.",390,"['Common stock, shares issued', 'Issued']",us-gaap_CommonStockSharesIssued,sharesItemType,ci,"(1) Par value per share, $0.01; shares issued, 394 million as of December 31, 2021 and 390 million as of December 31, 2020; authorized shares, 600 million.",390 million,CARDINAL,"1 Par value per share, $0.01; shares issued, 394 million as of December 31, 2021 and 390 million as of December 31, 2020; authorized shares, 600 million.","['Par value per share', 'shares']","['authorized shares', 0.691903293132782, 'What is 390 million ?', 'authorized shares']",authorized shares,0.691903293132782,What is 390 million ?,authorized shares,"shares issued as of December 31, 2020"
4,"(1) Par value per share, $0.01; shares issued, 394 million as of December 31, 2021 and 390 million as of December 31, 2020; authorized shares, 600 million.",600,"['Common stock, shares authorized']",us-gaap_CommonStockSharesAuthorized,sharesItemType,ci,"(1) Par value per share, $0.01; shares issued, 394 million as of December 31, 2021 and 390 million as of December 31, 2020; authorized shares, 600 million.",600 million,CARDINAL,"1 Par value per share, $0.01; shares issued, 394 million as of December 31, 2021 and 390 million as of December 31, 2020; authorized shares, 600 million.","['Par value per share', 'shares']","['authorized shares', 0.9932349324226379, 'What is 600 million ?', 'authorized shares']",authorized shares,0.993234932422638,What is 600 million ?,authorized shares,Authorized shares
5,"(1) Par value per share, $0.01; shares issued, 394 million as of December 31, 2021 and 390 million as of December 31, 2020; authorized shares, 600 million.",600,"['Common stock, shares authorized']",us-gaap_CommonStockSharesAuthorized,sharesItemType,ci,"(1) Par value per share, $0.01; shares issued, 394 million as of December 31, 2021 and 390 million as of December 31, 2020; authorized shares, 600 million.",600 million,CARDINAL,"1 Par value per share, $0.01; shares issued, 394 million as of December 31, 2021 and 390 million as of December 31, 2020; authorized shares, 600 million.","['Par value per share', 'shares']","['authorized shares', 0.9932349324226379, 'What is 600 million ?', 'authorized shares']",authorized shares,0.993234932422638,What is 600 million ?,authorized shares,Authorized shares
6,"(1) Includes $743 million reported in Assets of businesses held for sale as of January 1, 2020.",743,['Cash reclassified to assets of businesses held for sale'],us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations,monetaryItemType,ci,"(1) Includes $743 million reported in Assets of businesses held for sale as of January 1, 2020.",$743 million,MONEY,"1 Includes $743 million reported in Assets of businesses held for sale as of January 1, 2020.",['Assets of businesses'],"['', 0, '', '']",,0.0,,,Assets of businesses held for sale
7,"We entered into a definitive agreement in October 2021 to sell our life, accident and supplemental benefits businesses in seven countries to Chubb INA Holdings, Inc. (""Chubb"") for $5.75 billion cash (the ""Chubb Transaction""). See Note 5 for further information on the classification of these businesses as held for sale. In connection with the pending Chubb Transaction, we revised our business reporting structure. As such, we adjusted our segment reporting effective in the fourth quarter of 2021 so that the results previously reported in the International Markets segment are now reported as follows:",5.75,['Sale price'],us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration,monetaryItemType,ci,"We entered into a definitive agreement in October 2021 to sell our life, accident and supplemental benefits businesses in seven countries to Chubb INA Holdings, Inc. (""Chubb"") for $5.75 billion cash (the ""Chubb Transaction"").",$5.75 billion,MONEY,"We entered into a definitive agreement in October 2021 to sell our life, accident and supplemental benefits businesses in seven countries to Chubb INA Holdings, Inc.  for $5.75 billion cash .",['definitive agreement'],"['cash', 0.6375856399536133, 'What is $5.75 billion ?', 'cash']",cash,0.6375856399536133,What is $5.75 billion ?,cash,"definitive agreement to sell life, accident, and supplemental benefits businesses"
8,"Deferred policy acquisition costs also include the value of business acquired (""VOBA"") for certain acquisitions with material long duration insurance contracts. The Company recorded amortization of deferred policy acquisition costs of $478 million in 2021, $502 million in 2020 and $483 million in 2019 primarily in Selling, general and administrative expenses.",478,['Amortization of deferred policy acquisition costs'],us-gaap_DeferredPolicyAcquisitionCostAmortizationExpense,monetaryItemType,ci,"The Company recorded amortization of deferred policy acquisition costs of $478 million in 2021, $502 million in 2020 and $483 million in 2019 primarily in Selling, general and administrative expenses.",$478 million,MONEY,"The Company recorded amortization of deferred policy acquisition costs of $478 million in 2021, $502 million in 2020 and $483 million in 2019 primarily in Selling, general and administrative expenses.","['amortization of deferred acquisition costs', 'deferred acquisition costs', 'acquisition costs']","['amortization of deferred acquisition costs', 0.8201013207435608, 'what is amortization of deferred acquisition costs ?', '$478 million']",amortization of deferred acquisition costs,0.8201013207435608,what is amortization of deferred acquisition costs ?,$478 million,The Company recorded amortization of deferred policy acquisition costs
9,"Deferred policy acquisition costs also include the value of business acquired (""VOBA"") for certain acquisitions with material long duration insurance contracts. The Company recorded amortization of deferred policy acquisition costs of $478 million in 2021, $502 million in 2020 and $483 million in 2019 primarily in Selling, general and administrative expenses.",502,['Amortization of deferred policy acquisition costs'],us-gaap_DeferredPolicyAcquisitionCostAmortizationExpense,monetaryItemType,ci,"The Company recorded amortization of deferred policy acquisition costs of $478 million in 2021, $502 million in 2020 and $483 million in 2019 primarily in Selling, general and administrative expenses.",$502 million,MONEY,"The Company recorded amortization of deferred policy acquisition costs of $478 million in 2021, $502 million in 2020 and $483 million in 2019 primarily in Selling, general and administrative expenses.","['amortization of deferred acquisition costs', 'deferred acquisition costs', 'acquisition costs']","['', 0, '', '']",,0.0,,,Amortization of deferred policy acquisition costs
10,"Deferred policy acquisition costs also include the value of business acquired (""VOBA"") for certain acquisitions with material long duration insurance contracts. The Company recorded amortization of deferred policy acquisition costs of $478 million in 2021, $502 million in 2020 and $483 million in 2019 primarily in Selling, general and administrative expenses.",483,['Amortization of deferred policy acquisition costs'],us-gaap_DeferredPolicyAcquisitionCostAmortizationExpense,monetaryItemType,ci,"The Company recorded amortization of deferred policy acquisition costs of $478 million in 2021, $502 million in 2020 and $483 million in 2019 primarily in Selling, general and administrative expenses.",$483 million,MONEY,"The Company recorded amortization of deferred policy acquisition costs of $478 million in 2021, $502 million in 2020 and $483 million in 2019 primarily in Selling, general and administrative expenses.","['amortization of deferred acquisition costs', 'deferred acquisition costs', 'acquisition costs']","['', 0, '', '']",,0.0,,,Amortization of deferred policy acquisition costs
11,"for any estimated payouts within Accrued expenses and other liabilities (current). These estimates are adjusted at the end of the guarantee period. Historically, adjustments to original estimates have not been material. The performance guarantee liability was $1.1 billion as of December 31, 2021 and December 31, 2020.",1.1,"['Performance guarantee liability', 'Reserves for litigation matters, pre tax']",us-gaap_LossContingencyAccrualAtCarryingValue,monetaryItemType,ci,"The performance guarantee liability was $1.1 billion as of December 31, 2021 and December 31, 2020.",$1.1 billion,MONEY,"The performance guarantee liability was $1.1 billion as of December 31, 2021 and December 31, 2020.",['guarantee liability'],"['performance guarantee liability', 0.8381004929542542, 'What is $1.1 billion ?', 'performance guarantee liability']",performance guarantee liability,0.8381004929542542,What is $1.1 billion ?,performance guarantee liability,Performance guarantee liability
12,"for any estimated payouts within Accrued expenses and other liabilities (current). These estimates are adjusted at the end of the guarantee period. Historically, adjustments to original estimates have not been material. The performance guarantee liability was $1.1 billion as of December 31, 2021 and December 31, 2020.",1.1,"['Performance guarantee liability', 'Reserves for litigation matters, pre tax']",us-gaap_LossContingencyAccrualAtCarryingValue,monetaryItemType,ci,"The performance guarantee liability was $1.1 billion as of December 31, 2021 and December 31, 2020.",$1.1 billion,MONEY,"The performance guarantee liability was $1.1 billion as of December 31, 2021 and December 31, 2020.",['guarantee liability'],"['performance guarantee liability', 0.8381004929542542, 'What is $1.1 billion ?', 'performance guarantee liability']",performance guarantee liability,0.8381004929542542,What is $1.1 billion ?,performance guarantee liability,Performance guarantee liability
13,"These receivables are reported net of our allowances of $1.4 billion as of December 31, 2021 and $1.2 billion as of December 31, 2020 as follows:",1.4,['Allowance for receivables net current'],ci_AllowanceForReceivablesNetCurrent,monetaryItemType,ci,"These receivables are reported net of our allowances of $1.4 billion as of December 31, 2021 and $1.2 billion as of December 31, 2020 as follows:",$1.4 billion,MONEY,"These receivables are reported net of our allowances of $1.4 billion as of December 31, 2021 and $1.2 billion as of December 31, 2020 as follows:","['net of allowances', 'allowances', 'net', 'net']","['net of allowances', 0.9601694345474243, 'what is net of allowances ?', '$1.4 billion']",net of allowances,0.9601694345474244,what is net of allowances ?,$1.4 billion,"As of December 31, 2021

Entity:
$1.2 billion
Phrase:
As of December 31, 2020"
14,"These receivables are reported net of our allowances of $1.4 billion as of December 31, 2021 and $1.2 billion as of December 31, 2020 as follows:",1.2,['Allowance for receivables net current'],ci_AllowanceForReceivablesNetCurrent,monetaryItemType,ci,"These receivables are reported net of our allowances of $1.4 billion as of December 31, 2021 and $1.2 billion as of December 31, 2020 as follows:",$1.2 billion,MONEY,"These receivables are reported net of our allowances of $1.4 billion as of December 31, 2021 and $1.2 billion as of December 31, 2020 as follows:","['net of allowances', 'allowances', 'net', 'net']","['allowances', 0.16347597539424896, 'What is $1.2 billion ?', 'allowances']",allowances,0.1634759753942489,What is $1.2 billion ?,allowances,"As of December 31, 2020"
15,"•Included in our Pharmaceutical manufacturers receivable are contractual allowances for certain rebates receivable with pharmaceutical manufacturers of $926 million as of December 31, 2021 and $757 million as of December 31, 2020.",926,['Allowances for pharmaceutical manufacturers receivable'],ci_AllowanceForCreditLossPharmaceuticalManufacturersReceivable,monetaryItemType,ci,"•Included in our Pharmaceutical manufacturers receivable are contractual allowances for certain rebates receivable with pharmaceutical manufacturers of $926 million as of December 31, 2021 and $757 million as of December 31, 2020.",$926 million,MONEY,"•Included in our Pharmaceutical manufacturers receivable are contractual allowances for certain rebates receivable with pharmaceutical manufacturers of $926 million as of December 31, 2021 and $757 million as of December 31, 2020.","['contractual allowances for certain rebates', 'pharmaceutical manufacturers', 'Pharmaceutical manufacturers', 'certain rebates', 'pharmaceutical manufacturers']","['contractual allowances for certain rebates receivable with pharmaceutical manufacturers', 0.32900509238243103, 'What is $926 million ?', 'contractual allowances for certain rebates receivable with pharmaceutical manufacturers']",contractual allowances for certain rebates receivable with pharmaceutical manufacturers,0.329005092382431,What is $926 million ?,contractual allowances for certain rebates receivable with pharmaceutical manufacturers,Contractual allowances for certain rebates receivable with pharmaceutical manufacturers
16,"•Included in our Pharmaceutical manufacturers receivable are contractual allowances for certain rebates receivable with pharmaceutical manufacturers of $926 million as of December 31, 2021 and $757 million as of December 31, 2020.",757,['Allowances for pharmaceutical manufacturers receivable'],ci_AllowanceForCreditLossPharmaceuticalManufacturersReceivable,monetaryItemType,ci,"•Included in our Pharmaceutical manufacturers receivable are contractual allowances for certain rebates receivable with pharmaceutical manufacturers of $926 million as of December 31, 2021 and $757 million as of December 31, 2020.",$757 million,MONEY,"•Included in our Pharmaceutical manufacturers receivable are contractual allowances for certain rebates receivable with pharmaceutical manufacturers of $926 million as of December 31, 2021 and $757 million as of December 31, 2020.","['contractual allowances for certain rebates', 'pharmaceutical manufacturers', 'Pharmaceutical manufacturers', 'certain rebates', 'pharmaceutical manufacturers']","['', 0, '', '']",,0.0,,,Contractual allowances for rebates receivable
17,"•Included in our Noninsurance customer receivables are contractual allowances from third party payors of $321 million as of December 31, 2021 and $208 million as of December 31, 2020 based upon the contractual payment terms.",321,['Allowances for noninsurance customer receivables'],ci_AllowanceForCreditLossNoninsuranceCustomerReceivables,monetaryItemType,ci,"•Included in our Noninsurance customer receivables are contractual allowances from third party payors of $321 million as of December 31, 2021 and $208 million as of December 31, 2020 based upon the contractual payment terms.",$321 million,MONEY,"•Included in our Noninsurance customer receivables are contractual allowances from third party payors of $321 million as of December 31, 2021 and $208 million as of December 31, 2020 based upon the contractual payment terms.","['contractual allowances from party payors', 'party payors', 'Noninsurance customer receivables', 'party payors', 'contractual payment terms']","['contractual allowances from party payors', 0.9592039585113525, 'what is contractual allowances from party payors ?', '$321 million']",contractual allowances from party payors,0.9592039585113524,what is contractual allowances from party payors ?,$321 million,"As of December 31, 2021"
18,"•Included in our Noninsurance customer receivables are contractual allowances from third party payors of $321 million as of December 31, 2021 and $208 million as of December 31, 2020 based upon the contractual payment terms.",208,['Allowances for noninsurance customer receivables'],ci_AllowanceForCreditLossNoninsuranceCustomerReceivables,monetaryItemType,ci,"•Included in our Noninsurance customer receivables are contractual allowances from third party payors of $321 million as of December 31, 2021 and $208 million as of December 31, 2020 based upon the contractual payment terms.",$208 million,MONEY,"•Included in our Noninsurance customer receivables are contractual allowances from third party payors of $321 million as of December 31, 2021 and $208 million as of December 31, 2020 based upon the contractual payment terms.","['contractual allowances from party payors', 'party payors', 'Noninsurance customer receivables', 'party payors', 'contractual payment terms']","['contractual payment terms', 0.71006178855896, 'What is $208 million ?', 'contractual payment terms']",contractual payment terms,0.71006178855896,What is $208 million ?,contractual payment terms,Noninsurance customer receivables
19,"•The remaining allowances of $186 million as of December 31, 2021 and $224 million as of December 31, 2020 include allowances, discounts and claims adjustments issued to customers in the form of client credits, an allowance for current expected credit losses and other non credit adjustments.",186,"['Allowances, discounts and claims adjustments issued to customers in the form of client credits']",ci_AllowanceForReceivablesClientCredits,monetaryItemType,ci,"•The remaining allowances of $186 million as of December 31, 2021 and $224 million as of December 31, 2020 include allowances, discounts and claims adjustments issued to customers in the form of client credits, an allowance for current expected credit losses and other non credit adjustments.",$186 million,MONEY,"•The remaining allowances of $186 million as of December 31, 2021 and $224 million as of December 31, 2020 include allowances, discounts and claims adjustments issued to customers in the form of client credits, an allowance for current expected credit losses and other non credit adjustments.","['remaining allowances', 'remaining allowances', 'form of client credits', 'allowance for current expected credit losses', 'client credits', 'current credit losses']","['allowances', 0.5234490633010864, 'What is $186 million ?', 'allowances']",allowances,0.5234490633010864,What is $186 million ?,allowances,"Remaining allowances as of December 31, 2021"
20,"•The remaining allowances of $186 million as of December 31, 2021 and $224 million as of December 31, 2020 include allowances, discounts and claims adjustments issued to customers in the form of client credits, an allowance for current expected credit losses and other non credit adjustments.",224,"['Allowances, discounts and claims adjustments issued to customers in the form of client credits']",ci_AllowanceForReceivablesClientCredits,monetaryItemType,ci,"•The remaining allowances of $186 million as of December 31, 2021 and $224 million as of December 31, 2020 include allowances, discounts and claims adjustments issued to customers in the form of client credits, an allowance for current expected credit losses and other non credit adjustments.",$224 million,MONEY,"•The remaining allowances of $186 million as of December 31, 2021 and $224 million as of December 31, 2020 include allowances, discounts and claims adjustments issued to customers in the form of client credits, an allowance for current expected credit losses and other non credit adjustments.","['remaining allowances', 'remaining allowances', 'form of client credits', 'allowance for current expected credit losses', 'client credits', 'current credit losses']","['allowances', 0.46412378549575806, 'What is $224 million ?', 'allowances']",allowances,0.464123785495758,What is $224 million ?,allowances,"December 31, 2020"
21,"•The Company's allowance for current expected credit losses was $60 million as of December 31, 2021 and $65 million as of December 31, 2020.",60,['Allowance for current expected credit losses on accounts receivable'],us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent,monetaryItemType,ci,"•The Company's allowance for current expected credit losses was $60 million as of December 31, 2021 and $65 million as of December 31, 2020.",$60 million,MONEY,"•The Company's allowance for current expected credit losses was $60 million as of December 31, 2021 and $65 million as of December 31, 2020.","['allowance for current expected credit losses', 'current credit losses']","['allowance for current expected credit losses', 0.9156721830368042, 'what is allowance for current expected credit losses ?', '$60 million']",allowance for current expected credit losses,0.9156721830368042,what is allowance for current expected credit losses ?,$60 million,The company's allowance for current expected credit losses.
22,"•The Company's allowance for current expected credit losses was $60 million as of December 31, 2021 and $65 million as of December 31, 2020.",65,['Allowance for current expected credit losses on accounts receivable'],us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent,monetaryItemType,ci,"•The Company's allowance for current expected credit losses was $60 million as of December 31, 2021 and $65 million as of December 31, 2020.",$65 million,MONEY,"•The Company's allowance for current expected credit losses was $60 million as of December 31, 2021 and $65 million as of December 31, 2020.","['allowance for current expected credit losses', 'current credit losses']","[""The Company's allowance for current expected credit losses"", 0.11962241679430008, 'What is $65 million ?', ""The Company's allowance for current expected credit losses""]",The Company's allowance for current expected credit losses,0.1196224167943,What is $65 million ?,The Company's allowance for current expected credit losses,The Company's allowance for current expected credit losses
23,"On April 19, 2021, Cigna acquired 97% of MDLIVE, Inc. (""MDLIVE""), a 24/7 virtual care platform. Combined with Cigna's previously held equity investment, Cigna now owns 100% of MDLIVE. The acquisition of MDLIVE will enable Cigna's Evernorth segment to continue expanding access to virtual care and delivering a more affordable, convenient and connected care experience for consumers.",97,['Ownership interest acquired'],us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired,percentItemType,ci,"On April 19, 2021, Cigna acquired 97% of MDLIVE, Inc. (""MDLIVE""), a 24/7 virtual care platform.",97%,PERCENT,"On April 19, 2021, Cigna acquired 97% of MDLIVE, Inc. , a 247 virtual care platform.",['% of Inc.'],"['% of Inc.', 0.8030134439468384, 'what is % of Inc. ?', '97%']",% of Inc.,0.8030134439468384,what is % of Inc. ?,97%,Cigna acquired MDLIVE
24,"On April 19, 2021, Cigna acquired 97% of MDLIVE, Inc. (""MDLIVE""), a 24/7 virtual care platform. Combined with Cigna's previously held equity investment, Cigna now owns 100% of MDLIVE. The acquisition of MDLIVE will enable Cigna's Evernorth segment to continue expanding access to virtual care and delivering a more affordable, convenient and connected care experience for consumers.",100,['Ownership interest after acquisition'],us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeIncludingSubsequentAcquisitionPercentage,percentItemType,ci,"Combined with Cigna's previously held equity investment, Cigna now owns 100% of MDLIVE.",100%,PERCENT,"Combined with Cigna's previously held equity investment, Cigna now owns 100% of MDLIVE.","['% of MDLIVE', 'equity investment']","['% of MDLIVE', 0.9166200160980225, 'what is % of MDLIVE ?', '100%']",% of MDLIVE,0.9166200160980223,what is % of MDLIVE ?,100%,Cigna's equity investment
25,"The purchase price of $2.0 billion consisted of cash consideration. In accordance with GAAP, the total consideration transferred has been allocated to the tangible and intangible net assets acquired based on management's preliminary estimates of their fair values and may change as additional information becomes available over the next several months. As of December 31, 2021, the Company made immaterial measurement period adjustments to the purchase price allocation. The estimated fair values of assets acquired and liabilities assumed as of the closing date were as follows:",2.0,['Total purchase price'],us-gaap_BusinessCombinationConsiderationTransferred1,monetaryItemType,ci,The purchase price of $2.0 billion consisted of cash consideration.,$2.0 billion,MONEY,The purchase price of $2.0 billion consisted of cash consideration.,"['purchase price', 'cash consideration']","['purchase price', 0.9369339942932129, 'what is purchase price ?', '$2.0 billion']",purchase price,0.9369339942932128,what is purchase price ?,$2.0 billion,Cash consideration
26,"Substantially all of the goodwill is assigned to the Evernorth segment ($1.3 billion). Goodwill is not deductible for federal income tax purposes. The acquired intangible assets primarily consist of customer relationships ($577 million) as well as internal use software, provider networks and a trade name. The fair value of the customer relationships and the amortization period were determined using an income approach that relies heavily on projected future net cash flows including key assumptions for customer attrition, margins and discount rates. The customer relationship intangible asset is amortized over a period of 17 years in a pattern that reflects when Cigna expects to receive the benefits of the related cash flows.",1.3,['Goodwill'],us-gaap_Goodwill,monetaryItemType,ci,Substantially all of the goodwill is assigned to the Evernorth segment ($1.3 billion).,$1.3 billion,MONEY,Substantially all of the goodwill is assigned to the Evernorth segment $1.3 billion.,['Evernorth segment'],"['Evernorth segment', 0.9606281518936157, 'what is Evernorth segment ?', '$1.3 billion']",Evernorth segment,0.9606281518936156,what is Evernorth segment ?,$1.3 billion,Substantially all of the goodwill
27,"Substantially all of the goodwill is assigned to the Evernorth segment ($1.3 billion). Goodwill is not deductible for federal income tax purposes. The acquired intangible assets primarily consist of customer relationships ($577 million) as well as internal use software, provider networks and a trade name. The fair value of the customer relationships and the amortization period were determined using an income approach that relies heavily on projected future net cash flows including key assumptions for customer attrition, margins and discount rates. The customer relationship intangible asset is amortized over a period of 17 years in a pattern that reflects when Cigna expects to receive the benefits of the related cash flows.",577,"['Other intangible assets', 'Net Carrying Value', 'Acquired intangible assets']",us-gaap_IntangibleAssetsNetExcludingGoodwill,monetaryItemType,ci,"The acquired intangible assets primarily consist of customer relationships ($577 million) as well as internal use software, provider networks and a trade name.",$577 million,MONEY,"The acquired intangible assets primarily consist of customer relationships $577 million as well as internal use software, provider networks and a trade name.","['intangible assets', 'customer relationships']","['customer relationships', 0.9677127599716187, 'What is $577 million ?', 'customer relationships']",customer relationships,0.9677127599716188,What is $577 million ?,customer relationships,Intangible assets customer relationships
28,"Substantially all of the goodwill is assigned to the Evernorth segment ($1.3 billion). Goodwill is not deductible for federal income tax purposes. The acquired intangible assets primarily consist of customer relationships ($577 million) as well as internal use software, provider networks and a trade name. The fair value of the customer relationships and the amortization period were determined using an income approach that relies heavily on projected future net cash flows including key assumptions for customer attrition, margins and discount rates. The customer relationship intangible asset is amortized over a period of 17 years in a pattern that reflects when Cigna expects to receive the benefits of the related cash flows.",17,['Amortization period'],us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife,durationItemType,ci,The customer relationship intangible asset is amortized over a period of 17 years in a pattern that reflects when Cigna expects to receive the benefits of the related cash flows.,17 years,DATE,The customer relationship intangible asset is amortized over a period of 17 years in a pattern that reflects when Cigna expects to receive the benefits of the related cash flows.,"['period of years', 'period in pattern', 'benefits of related cash flows', 'intangible asset', 'related cash flows']","['The customer relationship intangible asset', 0.473712295293808, 'What is 17 years ?', 'The customer relationship intangible asset']",The customer relationship intangible asset,0.473712295293808,What is 17 years ?,The customer relationship intangible asset,The customer relationship intangible asset
29,"On December 31, 2020, Cigna completed the sale of its U.S. Group Disability and Life business to New York Life Insurance Company for cash proceeds of $6.2 billion. The Company recognized a gain of $4.2 billion pre tax ($3.2 billion after tax), which included recognition of previously unrealized capital gains on investments sold (see Note 14 for further information).",6.2,['Cash proceeds from sale of business'],us-gaap_ProceedsFromDivestitureOfBusinesses,monetaryItemType,ci,"On December 31, 2020, Cigna completed the sale of its U.S. Group Disability and Life business to New York Life Insurance Company for cash proceeds of $6.2 billion.",$6.2 billion,MONEY,"On December 31, 2020, Cigna completed the sale of its U.S. Group Disability and Life business to New York Life Insurance Company for cash proceeds of $6.2 billion.","['sale of business', 'sale to York Insurance Company', 'sale for cash proceeds', 'cash proceeds', 'cash proceeds']","['cash proceeds', 0.9267352819442749, 'what is cash proceeds ?', '$6.2 billion']",cash proceeds,0.9267352819442748,what is cash proceeds ?,$6.2 billion,sale of U.S. Group Disability and Life business
30,"On December 31, 2020, Cigna completed the sale of its U.S. Group Disability and Life business to New York Life Insurance Company for cash proceeds of $6.2 billion. The Company recognized a gain of $4.2 billion pre tax ($3.2 billion after tax), which included recognition of previously unrealized capital gains on investments sold (see Note 14 for further information).",4.2,"['Gain  on sale of business, pre tax']",us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal,monetaryItemType,ci,"The Company recognized a gain of $4.2 billion pre tax ($3.2 billion after tax), which included recognition of previously unrealized capital gains on investments sold (see Note 14 for further information).",$4.2 billion,MONEY,"The Company recognized a gain of $4.2 billion pre tax $3.2 billion after tax, which included recognition of previously unrealized capital gains on investments sold see Note 14 for further information.","['gain of pre tax', 'recognition of unrealized capital gains', 'unrealized capital gains on investments', 'pre tax', 'unrealized capital gains', 'further information']","['pre tax', 0.23066458106040955, 'What is $4.2 billion ?', 'pre tax']",pre tax,0.2306645810604095,What is $4.2 billion ?,pre tax,"The Company recognized a gain

Entity: 
$3.2 billion
Phrase: 
The Company recognized a gain"
31,"On December 31, 2020, Cigna completed the sale of its U.S. Group Disability and Life business to New York Life Insurance Company for cash proceeds of $6.2 billion. The Company recognized a gain of $4.2 billion pre tax ($3.2 billion after tax), which included recognition of previously unrealized capital gains on investments sold (see Note 14 for further information).",3.2,"['Gain  on sale of business, after tax']",ci_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalNetOfTax,monetaryItemType,ci,"The Company recognized a gain of $4.2 billion pre tax ($3.2 billion after tax), which included recognition of previously unrealized capital gains on investments sold (see Note 14 for further information).",$3.2 billion,MONEY,"The Company recognized a gain of $4.2 billion pre tax $3.2 billion after tax, which included recognition of previously unrealized capital gains on investments sold see Note 14 for further information.","['gain of pre tax', 'recognition of unrealized capital gains', 'unrealized capital gains on investments', 'pre tax', 'unrealized capital gains', 'further information']","['pre tax', 0.9772911071777344, 'what is pre tax ?', '$3.2 billion']",pre tax,0.9772911071777344,what is pre tax ?,$3.2 billion,Recognized gain from investments
32,"In 2021, the Company incurred costs related to the acquisition of MDLIVE, the sale of the U.S. Group Disability and Life business, the terminated merger with Anthem, Inc. (""Anthem"") and the pending Chubb Transaction (see Note 5 for further information on assets and liabilities of businesses held for sale). In 2020 and 2019, the Company incurred costs related to the acquisition and integration of Express Scripts Holding Company (""Express Scripts""), the terminated merger with Anthem, the sale of the U.S. Group Disability and Life insurance business and other transactions. These costs were $169 million pre tax ($71 million after tax) for the year ended December 31, 2021, compared with $527 million pre tax ($404 million after tax) for the year ended December 31, 2020 and $552 million pre tax ($427 million after tax) for the year ended December 31, 2019. These costs consisted primarily of certain projects to integrate or separate the Company's systems, products and services, fees for legal, advisory and other professional services and certain employment related costs. After tax costs for the year ended December 31, 2021 included a tax benefit from the resolution of a tax matter related to the sold Group Disability and Life business.",169,"['Integration and transaction related  costs', 'Integration and transaction related costs, pre tax']",ci_TransactionRelatedCosts,monetaryItemType,ci,"These costs were $169 million pre tax ($71 million after tax) for the year ended December 31, 2021, compared with $527 million pre tax ($404 million after tax) for the year ended December 31, 2020 and $552 million pre tax ($427 million after tax) for the year ended December 31, 2019.",$169 million,MONEY,"These costs were $169 million pre tax $71 million after tax for the year ended December 31, 2021, compared with $527 million pre tax $404 million after tax for the year ended December 31, 2020 and $552 million pre tax $427 million after tax for the year ended December 31, 2019.","['tax for year', 'pre tax after tax', 'tax for year', 'tax for year', 'pre tax', 'pre tax']","['', 0, '', '']",,0.0,,,"Pre tax costs for the year ended December 31, 2021."
33,"In 2021, the Company incurred costs related to the acquisition of MDLIVE, the sale of the U.S. Group Disability and Life business, the terminated merger with Anthem, Inc. (""Anthem"") and the pending Chubb Transaction (see Note 5 for further information on assets and liabilities of businesses held for sale). In 2020 and 2019, the Company incurred costs related to the acquisition and integration of Express Scripts Holding Company (""Express Scripts""), the terminated merger with Anthem, the sale of the U.S. Group Disability and Life insurance business and other transactions. These costs were $169 million pre tax ($71 million after tax) for the year ended December 31, 2021, compared with $527 million pre tax ($404 million after tax) for the year ended December 31, 2020 and $552 million pre tax ($427 million after tax) for the year ended December 31, 2019. These costs consisted primarily of certain projects to integrate or separate the Company's systems, products and services, fees for legal, advisory and other professional services and certain employment related costs. After tax costs for the year ended December 31, 2021 included a tax benefit from the resolution of a tax matter related to the sold Group Disability and Life business.",71,"['Integration and transaction related  costs', 'Integration and transaction related costs, after tax']",ci_TransactionRelatedCostsAfterTax,monetaryItemType,ci,"These costs were $169 million pre tax ($71 million after tax) for the year ended December 31, 2021, compared with $527 million pre tax ($404 million after tax) for the year ended December 31, 2020 and $552 million pre tax ($427 million after tax) for the year ended December 31, 2019.",$71 million,MONEY,"These costs were $169 million pre tax $71 million after tax for the year ended December 31, 2021, compared with $527 million pre tax $404 million after tax for the year ended December 31, 2020 and $552 million pre tax $427 million after tax for the year ended December 31, 2019.","['tax for year', 'pre tax after tax', 'tax for year', 'tax for year', 'pre tax', 'pre tax']","['pre tax', 0.6465831995010376, 'What is $71 million ?', 'pre tax']",pre tax,0.6465831995010376,What is $71 million ?,pre tax,"after tax for the year ended December 31, 2021"
34,"In 2021, the Company incurred costs related to the acquisition of MDLIVE, the sale of the U.S. Group Disability and Life business, the terminated merger with Anthem, Inc. (""Anthem"") and the pending Chubb Transaction (see Note 5 for further information on assets and liabilities of businesses held for sale). In 2020 and 2019, the Company incurred costs related to the acquisition and integration of Express Scripts Holding Company (""Express Scripts""), the terminated merger with Anthem, the sale of the U.S. Group Disability and Life insurance business and other transactions. These costs were $169 million pre tax ($71 million after tax) for the year ended December 31, 2021, compared with $527 million pre tax ($404 million after tax) for the year ended December 31, 2020 and $552 million pre tax ($427 million after tax) for the year ended December 31, 2019. These costs consisted primarily of certain projects to integrate or separate the Company's systems, products and services, fees for legal, advisory and other professional services and certain employment related costs. After tax costs for the year ended December 31, 2021 included a tax benefit from the resolution of a tax matter related to the sold Group Disability and Life business.",527,"['Integration and transaction related  costs', 'Integration and transaction related costs, pre tax']",ci_TransactionRelatedCosts,monetaryItemType,ci,"These costs were $169 million pre tax ($71 million after tax) for the year ended December 31, 2021, compared with $527 million pre tax ($404 million after tax) for the year ended December 31, 2020 and $552 million pre tax ($427 million after tax) for the year ended December 31, 2019.",$527 million,MONEY,"These costs were $169 million pre tax $71 million after tax for the year ended December 31, 2021, compared with $527 million pre tax $404 million after tax for the year ended December 31, 2020 and $552 million pre tax $427 million after tax for the year ended December 31, 2019.","['tax for year', 'pre tax after tax', 'tax for year', 'tax for year', 'pre tax', 'pre tax']","['', 0, '', '']",,0.0,,,"Pre tax costs for the year ended December 31, 2020"
35,"In 2021, the Company incurred costs related to the acquisition of MDLIVE, the sale of the U.S. Group Disability and Life business, the terminated merger with Anthem, Inc. (""Anthem"") and the pending Chubb Transaction (see Note 5 for further information on assets and liabilities of businesses held for sale). In 2020 and 2019, the Company incurred costs related to the acquisition and integration of Express Scripts Holding Company (""Express Scripts""), the terminated merger with Anthem, the sale of the U.S. Group Disability and Life insurance business and other transactions. These costs were $169 million pre tax ($71 million after tax) for the year ended December 31, 2021, compared with $527 million pre tax ($404 million after tax) for the year ended December 31, 2020 and $552 million pre tax ($427 million after tax) for the year ended December 31, 2019. These costs consisted primarily of certain projects to integrate or separate the Company's systems, products and services, fees for legal, advisory and other professional services and certain employment related costs. After tax costs for the year ended December 31, 2021 included a tax benefit from the resolution of a tax matter related to the sold Group Disability and Life business.",404,"['Integration and transaction related  costs', 'Integration and transaction related costs, after tax']",ci_TransactionRelatedCostsAfterTax,monetaryItemType,ci,"These costs were $169 million pre tax ($71 million after tax) for the year ended December 31, 2021, compared with $527 million pre tax ($404 million after tax) for the year ended December 31, 2020 and $552 million pre tax ($427 million after tax) for the year ended December 31, 2019.",$404 million,MONEY,"These costs were $169 million pre tax $71 million after tax for the year ended December 31, 2021, compared with $527 million pre tax $404 million after tax for the year ended December 31, 2020 and $552 million pre tax $427 million after tax for the year ended December 31, 2019.","['tax for year', 'pre tax after tax', 'tax for year', 'tax for year', 'pre tax', 'pre tax']","['pre tax', 0.9445323944091797, 'what is pre tax ?', '$404 million']",pre tax,0.9445323944091796,what is pre tax ?,$404 million,"After tax for the year ended December 31, 2020"
36,"In 2021, the Company incurred costs related to the acquisition of MDLIVE, the sale of the U.S. Group Disability and Life business, the terminated merger with Anthem, Inc. (""Anthem"") and the pending Chubb Transaction (see Note 5 for further information on assets and liabilities of businesses held for sale). In 2020 and 2019, the Company incurred costs related to the acquisition and integration of Express Scripts Holding Company (""Express Scripts""), the terminated merger with Anthem, the sale of the U.S. Group Disability and Life insurance business and other transactions. These costs were $169 million pre tax ($71 million after tax) for the year ended December 31, 2021, compared with $527 million pre tax ($404 million after tax) for the year ended December 31, 2020 and $552 million pre tax ($427 million after tax) for the year ended December 31, 2019. These costs consisted primarily of certain projects to integrate or separate the Company's systems, products and services, fees for legal, advisory and other professional services and certain employment related costs. After tax costs for the year ended December 31, 2021 included a tax benefit from the resolution of a tax matter related to the sold Group Disability and Life business.",552,"['Integration and transaction related  costs', 'Integration and transaction related costs, pre tax']",ci_TransactionRelatedCosts,monetaryItemType,ci,"These costs were $169 million pre tax ($71 million after tax) for the year ended December 31, 2021, compared with $527 million pre tax ($404 million after tax) for the year ended December 31, 2020 and $552 million pre tax ($427 million after tax) for the year ended December 31, 2019.",$552 million,MONEY,"These costs were $169 million pre tax $71 million after tax for the year ended December 31, 2021, compared with $527 million pre tax $404 million after tax for the year ended December 31, 2020 and $552 million pre tax $427 million after tax for the year ended December 31, 2019.","['tax for year', 'pre tax after tax', 'tax for year', 'tax for year', 'pre tax', 'pre tax']","['', 0, '', '']",,0.0,,,"Pre tax costs for the year ended December 31, 2019"
37,"In 2021, the Company incurred costs related to the acquisition of MDLIVE, the sale of the U.S. Group Disability and Life business, the terminated merger with Anthem, Inc. (""Anthem"") and the pending Chubb Transaction (see Note 5 for further information on assets and liabilities of businesses held for sale). In 2020 and 2019, the Company incurred costs related to the acquisition and integration of Express Scripts Holding Company (""Express Scripts""), the terminated merger with Anthem, the sale of the U.S. Group Disability and Life insurance business and other transactions. These costs were $169 million pre tax ($71 million after tax) for the year ended December 31, 2021, compared with $527 million pre tax ($404 million after tax) for the year ended December 31, 2020 and $552 million pre tax ($427 million after tax) for the year ended December 31, 2019. These costs consisted primarily of certain projects to integrate or separate the Company's systems, products and services, fees for legal, advisory and other professional services and certain employment related costs. After tax costs for the year ended December 31, 2021 included a tax benefit from the resolution of a tax matter related to the sold Group Disability and Life business.",427,"['Integration and transaction related  costs', 'Integration and transaction related costs, after tax']",ci_TransactionRelatedCostsAfterTax,monetaryItemType,ci,"These costs were $169 million pre tax ($71 million after tax) for the year ended December 31, 2021, compared with $527 million pre tax ($404 million after tax) for the year ended December 31, 2020 and $552 million pre tax ($427 million after tax) for the year ended December 31, 2019.",$427 million,MONEY,"These costs were $169 million pre tax $71 million after tax for the year ended December 31, 2021, compared with $527 million pre tax $404 million after tax for the year ended December 31, 2020 and $552 million pre tax $427 million after tax for the year ended December 31, 2019.","['tax for year', 'pre tax after tax', 'tax for year', 'tax for year', 'pre tax', 'pre tax']","['', 0, '', '']",,0.0,,,"After tax for the year ended December 31, 2019"
38,"Cigna entered into a definitive agreement in October 2021 to sell its life, accident and supplemental benefits businesses in seven countries to Chubb for $5.75 billion cash. Subject to applicable regulatory approvals and customary closing conditions, we expect to complete the sale of our life, accident and supplemental benefits businesses in Hong Kong, Indonesia, New Zealand, South Korea, Taiwan, Thailand and our interest in a joint venture in Turkey in the second quarter of 2022. The Company believes this sale is probable and has aggregated and classified the assets and liabilities directly associated with the pending sale as held for sale and has reported them separately on our Consolidated Balance Sheets as of December 31, 2021. The assets and liabilities of businesses held for sale were as follows:(In millions)December 31, 2021Cash and cash equivalents$406 Investments5,109 Deferred policy acquisition costs2,755 Separate account assets878 Goodwill, other intangible assets and all other assets909 Total assets of business held for sale10,057 Insurance and contractholder liabilities4,644 Accounts payable, accrued expenses and other liabilities452 Deferred tax liabilities, net449 Separate account liabilities878 Total liabilities of business held for sale$6,423",5.75,['Sale price'],us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration,monetaryItemType,ci,"Cigna entered into a definitive agreement in October 2021 to sell its life, accident and supplemental benefits businesses in seven countries to Chubb for $5.75 billion cash.",$5.75 billion,MONEY,"Cigna entered into a definitive agreement in October 2021 to sell its life, accident and supplemental benefits businesses in seven countries to Chubb for $5.75 billion cash.",['definitive agreement'],"['', 0, '', '']",,0.0,,,"Cigna's life, accident, and supplemental benefits businesses"
39,"The held for sale businesses reported Redeemable noncontrolling interests of $24 million, Gross unrealized appreciation on securities and derivatives of $137 million and Gross translation loss on foreign currencies of $209 million on our Consolidated Balance Sheets as of December 31, 2021.",24,['Redeemable noncontrolling interests'],ci_DisposalGroupIncludingDiscontinuedOperationsRedeemableNoncontrollingInterestEquityCarryingAmount,monetaryItemType,ci,"The held for sale businesses reported Redeemable noncontrolling interests of $24 million, Gross unrealized appreciation on securities and derivatives of $137 million and Gross translation loss on foreign currencies of $209 million on our Consolidated Balance Sheets as of December 31, 2021.",$24 million,MONEY,"The held for sale businesses reported Redeemable noncontrolling interests of $24 million, Gross unrealized appreciation on securities and derivatives of $137 million and Gross translation loss on foreign currencies of $209 million on our Consolidated Balance Sheets as of December 31, 2021.","['Redeemable noncontrolling interests', 'Gross unrealized appreciation on securities', 'securities', 'Gross translation loss on foreign currencies', 'foreign currencies', 'Gross translation loss on Consolidated Balance Sheets', 'Gross unrealized appreciation', 'sale businesses', 'Redeemable interests', 'foreign currencies']","['Redeemable noncontrolling interests', 0.8964613676071167, 'what is Redeemable noncontrolling interests ?', '$24 million']",Redeemable noncontrolling interests,0.8964613676071167,what is Redeemable noncontrolling interests ?,$24 million,"Redeemable noncontrolling interests

Entity:
$137 million
Phrase: 
Gross unrealized appreciation on securities and derivatives

Entity: 
$209 million
Phrase: 
Gross translation loss on foreign currencies"
40,"The held for sale businesses reported Redeemable noncontrolling interests of $24 million, Gross unrealized appreciation on securities and derivatives of $137 million and Gross translation loss on foreign currencies of $209 million on our Consolidated Balance Sheets as of December 31, 2021.",137,['Gross unrealized appreciation on securities and derivatives'],ci_DisposalGroupIncludingDiscontinuedOperationsAccumulatedGrossUnrealizedGainLossInvestmentsAndDerivatives,monetaryItemType,ci,"The held for sale businesses reported Redeemable noncontrolling interests of $24 million, Gross unrealized appreciation on securities and derivatives of $137 million and Gross translation loss on foreign currencies of $209 million on our Consolidated Balance Sheets as of December 31, 2021.",$137 million,MONEY,"The held for sale businesses reported Redeemable noncontrolling interests of $24 million, Gross unrealized appreciation on securities and derivatives of $137 million and Gross translation loss on foreign currencies of $209 million on our Consolidated Balance Sheets as of December 31, 2021.","['Redeemable noncontrolling interests', 'Gross unrealized appreciation on securities', 'securities', 'Gross translation loss on foreign currencies', 'foreign currencies', 'Gross translation loss on Consolidated Balance Sheets', 'Gross unrealized appreciation', 'sale businesses', 'Redeemable interests', 'foreign currencies']","['Gross unrealized appreciation on securities', 0.950730562210083, 'what is Gross unrealized appreciation on securities ?', '$137 million']",Gross unrealized appreciation on securities,0.950730562210083,what is Gross unrealized appreciation on securities ?,$137 million,Gross unrealized appreciation on securities and derivatives
41,"The held for sale businesses reported Redeemable noncontrolling interests of $24 million, Gross unrealized appreciation on securities and derivatives of $137 million and Gross translation loss on foreign currencies of $209 million on our Consolidated Balance Sheets as of December 31, 2021.",209,[],ci_DisposalGroupIncludingDiscontinuedOperationsAccumulatedGrossUnrealizedGainLossForeignCurrencyTranslation,monetaryItemType,ci,"The held for sale businesses reported Redeemable noncontrolling interests of $24 million, Gross unrealized appreciation on securities and derivatives of $137 million and Gross translation loss on foreign currencies of $209 million on our Consolidated Balance Sheets as of December 31, 2021.",$209 million,MONEY,"The held for sale businesses reported Redeemable noncontrolling interests of $24 million, Gross unrealized appreciation on securities and derivatives of $137 million and Gross translation loss on foreign currencies of $209 million on our Consolidated Balance Sheets as of December 31, 2021.","['Redeemable noncontrolling interests', 'Gross unrealized appreciation on securities', 'securities', 'Gross translation loss on foreign currencies', 'foreign currencies', 'Gross translation loss on Consolidated Balance Sheets', 'Gross unrealized appreciation', 'sale businesses', 'Redeemable interests', 'foreign currencies']","['Gross translation loss on foreign currencies', 0.9771865010261536, 'what is Gross translation loss on foreign currencies ?', '$209 million']",Gross translation loss on foreign currencies,0.9771865010261536,what is Gross translation loss on foreign currencies ?,$209 million,Gross translation loss on foreign currencies
42,"•Debt issuance: On March 3, 2021, the Company issued $4.3 billion of new senior notes. The proceeds of this issuance were mainly used to redeem outstanding debt securities. The remaining proceeds are available for general corporate purposes. Interest on this debt is paid semi annually.",4.3,"['Principal', 'Principal']",us-gaap_DebtInstrumentFaceAmount,monetaryItemType,ci,"•Debt issuance: On March 3, 2021, the Company issued $4.3 billion of new senior notes.",$4.3 billion,MONEY,"•Debt issuance: On March 3, 2021, the Company issued $4.3 billion of new senior notes.",['new senior notes'],"['new senior notes', 0.9372660517692566, 'what is new senior notes ?', '$4.3 billion']",new senior notes,0.9372660517692566,what is new senior notes ?,$4.3 billion,New senior notes
43,"(1) Redeemable at any time discounted at the U.S. Treasury rate plus 7.5 basis points. Redeemable at par on or after March 15, 2022.",7.5,"['Redemption price discount, spread on variable rate']",ci_DebtInstrumentRedemptionPriceDiscountSpreadOnVariableRate,pureItemType,ci,(1) Redeemable at any time discounted at the U.S. Treasury rate plus 7.5 basis points.,7.5,CARDINAL,1 Redeemable at any time discounted at the U.S. Treasury rate plus 7.5 basis points.,"['Redeemable at time', 'U.S. Treasury rate']","['basis points', 0.9873620271682739, 'What is 7.5 ?', 'basis points']",basis points,0.987362027168274,What is 7.5 ?,basis points,U.S. Treasury rate
44,"(2) Redeemable at any time discounted at the U.S. Treasury rate plus 10 basis points. Redeemable at par on or after February 15, 2026.",10,"['Redemption price discount, spread on variable rate']",ci_DebtInstrumentRedemptionPriceDiscountSpreadOnVariableRate,pureItemType,ci,(2) Redeemable at any time discounted at the U.S. Treasury rate plus 10 basis points.,10,CARDINAL,2 Redeemable at any time discounted at the U.S. Treasury rate plus 10 basis points.,"['Redeemable at time', 'U.S. Treasury rate']","['basis points', 0.9555671215057373, 'What is 10 ?', 'basis points']",basis points,0.9555671215057372,What is 10 ?,basis points,Redeemable at any time
45,"(3) Redeemable at any time discounted at the U.S. Treasury rate plus 15 basis points. Redeemable at par on or after December 15, 2030.",15,"['Redemption price discount, spread on variable rate']",ci_DebtInstrumentRedemptionPriceDiscountSpreadOnVariableRate,pureItemType,ci,(3) Redeemable at any time discounted at the U.S. Treasury rate plus 15 basis points.,15,CARDINAL,3 Redeemable at any time discounted at the U.S. Treasury rate plus 15 basis points.,"['Redeemable at time', 'U.S. Treasury rate']","['basis points', 0.9415246844291687, 'What is 15 ?', 'basis points']",basis points,0.9415246844291688,What is 15 ?,basis points,Basis points
46,"(4) Redeemable at any time discounted at the U.S. Treasury rate plus 20 basis points. Redeemable at par on or after September 15, 2050.",20,"['Redemption price discount, spread on variable rate']",ci_DebtInstrumentRedemptionPriceDiscountSpreadOnVariableRate,pureItemType,ci,(4) Redeemable at any time discounted at the U.S. Treasury rate plus 20 basis points.,20,CARDINAL,4 Redeemable at any time discounted at the U.S. Treasury rate plus 20 basis points.,"['Redeemable at time', 'U.S. Treasury rate']","['basis points', 0.831128716468811, 'What is 20 ?', 'basis points']",basis points,0.831128716468811,What is 20 ?,basis points,Redeemable at any time
47,"•Debt redemption: During 2021, the Company completed the redemption of a total of $4.5 billion in aggregate principal amount of certain of its outstanding debt securities. The Company recorded a pre tax loss of $141 million ($110 million after tax), consisting primarily of premium payments.",4.5,['Aggregate principal amount of outstanding debt securities redeemed'],us-gaap_DebtInstrumentRepurchasedFaceAmount,monetaryItemType,ci,"•Debt redemption: During 2021, the Company completed the redemption of a total of $4.5 billion in aggregate principal amount of certain of its outstanding debt securities.",$4.5 billion,MONEY,"•Debt redemption: During 2021, the Company completed the redemption of a total of $4.5 billion in aggregate principal amount of certain of its outstanding debt securities.","['redemption of total', 'total', 'aggregate principal amount', 'aggregate principal amount', 'outstanding debt securities']","['redemption of total', 0.8630295991897583, 'what is redemption of total ?', '$4.5 billion']",redemption of total,0.8630295991897583,what is redemption of total ?,$4.5 billion,Debt securities redemption
48,"•Debt redemption: During 2021, the Company completed the redemption of a total of $4.5 billion in aggregate principal amount of certain of its outstanding debt securities. The Company recorded a pre tax loss of $141 million ($110 million after tax), consisting primarily of premium payments.",141,"['Debt extinguishment costs', 'Debt extinguishment costs']",us-gaap_GainsLossesOnExtinguishmentOfDebt,monetaryItemType,ci,"The Company recorded a pre tax loss of $141 million ($110 million after tax), consisting primarily of premium payments.",$141 million,MONEY,"The Company recorded a pre tax loss of $141 million $110 million after tax, consisting primarily of premium payments.","['pre tax loss', 'pre tax loss']","['pre tax loss', 0.2828208804130554, 'what is pre tax loss ?', '$141 million $110 million after tax, consisting primarily of premium payments']",pre tax loss,0.2828208804130554,what is pre tax loss ?,"$141 million $110 million after tax, consisting primarily of premium payments","Pre-tax loss

Entity: 
$110 million
Phrase: 
After-tax loss"
49,"•Debt redemption: During 2021, the Company completed the redemption of a total of $4.5 billion in aggregate principal amount of certain of its outstanding debt securities. The Company recorded a pre tax loss of $141 million ($110 million after tax), consisting primarily of premium payments.",110,[],ci_GainLossOnExtinguishmentOfDebtNetOfTax,monetaryItemType,ci,"The Company recorded a pre tax loss of $141 million ($110 million after tax), consisting primarily of premium payments.",$110 million,MONEY,"The Company recorded a pre tax loss of $141 million $110 million after tax, consisting primarily of premium payments.","['pre tax loss', 'pre tax loss']","['pre tax loss', 0.2828208804130554, 'what is pre tax loss ?', '$141 million $110 million after tax, consisting primarily of premium payments']",pre tax loss,0.2828208804130554,what is pre tax loss ?,"$141 million $110 million after tax, consisting primarily of premium payments",After-tax loss
